The pharmaceutical company Almirall, a member of CATALONIA.HEALTH, announced at the JPMorgan HealthCare 2025 Conference, an update of its strategy and business perspectives. The president and CEO of Almirall, Carlos Gallardo, highlighted the company’s entry into a new era for the business, predicting sustained double-digit growth and substantial expansion of margins from 2025. Everything is driven by its strategy focused on medical dermatology, commercial excellence and its continuous investment in R&D to innovate and advance in science.
Almirall has solid growth engines in both biological treatments and continuous growth in medical dermatology, with key treatments such as Klisyri, Wynzora and Seysara. The solid performance of Almirall's main growth engines has allowed it to adjust the expected peak sales for biological treatments, exceeding 800 million of euros, with sales for Ebglyss of more than 450 million of euros and Ilumetri above 300 million of euros.
Almirall remains committed to innovation and will continue to invest in its R&D capabilities in medical dermatology, boosting its scientific leadership, building sustainable future growth and allowing millions of people access to transformative and innovative treatments. The company has invested around 12% of its net sales in R&D for many years, laying the foundations for continuous growth and acceleration in the future and creating and advancing development in key areas of its portfolio, both in clinical and preclinical phases.
“2025 is a turning point for Almirall, as we are entering an era of sustained two-digit growth and increased profit margins. We are dedicated to improving the lives of patients and advancing medical dermatology through our leading research and development initiatives, thus giving patients access to innovative treatment options”, says Carlos Gallardo, CEO and president of Almirall. “We will continue our sustained investment in R&D to lead science, innovation and excellence in medical dermatology. Almirall is a strategic partner for dermatologists and together we will have a positive impact on the lives of more patients while growing up in our company.”
Related news:
Comments